期刊文献+
共找到276篇文章
< 1 2 14 >
每页显示 20 50 100
Systematic evaluation and meta-analysis of the efficacy and safety of cinobufagin injection combined with western medicine in the treatment of liver cancer
1
作者 REN Si-si FAN Yu +4 位作者 GUO Dong-yan ZHAI Bing-tao LI Jing-tao SHI Xiao-yan DUAN Li-fang 《Journal of Hainan Medical University》 CAS 2023年第6期51-61,共11页
Objective:To evaluate the clinical efficacy and safety of cinobufagin injection in the treatment of liver cancer.Methods:PubMed database,Embase database and Cochrane Library database,CNKI,Wanfang database,VIP database... Objective:To evaluate the clinical efficacy and safety of cinobufagin injection in the treatment of liver cancer.Methods:PubMed database,Embase database and Cochrane Library database,CNKI,Wanfang database,VIP database and Sinomed database were used to search for the randomized controlled trials of cinobufagin injection combined with Western medicine in the treatment of primary liver cancer.The retrieval time was from the establishment to December 15,2020.Two independent researchers conducted systematic screening,literature inclusion and quality assessment of the articles according to the inclusion criteria,respectively.Meta-analysis of the data was performed using RevMan 5.4 software.Results:A total of 30 studies with a total of 2355 patients were included.Compared with conventional western medicine treatment,the clinical effective rate of Hububutin injection combined with western medicine was significantly higher[RR=1.16,95%CI=(1.11,1.22),P<0.00001].It could effectively reduce the tumor size[RR=1.33,95%CI=(1.17,1.51),P<0.00001],prolong the survival time of patients[RR=1.41,95%CI=(1.31,1.52),P<0.00001],improve the quality of life[RR=1.37,95%CI=(1.19,1.57),P<0.00001],improve the liver function of patients[RR=-14.52,95%CI=(-16.15,-12.88),P<0.00001],and reduce the occurrence of adverse reactions[RR=0.94,95%CI=(0.85,1.42),P=0.25]such as bone marrow suppression[RR=0.44,95%CI=(0.31,0.62),P<0.00001].Conclusion:Cinobufagin injection combined with western medicine therapy can effectively improve the clinical symptoms of primary liver cancer,and the safety is good.However,the methodological quality of the included literature is low,which affects the objectivity of the outcome,and it still needs to be verified by multi-sample,multi-center,randomized double-blind controlled trial. 展开更多
关键词 cinobufagin injection Primary liver cancer META-ANALYSIS EFFECTIVENESS SECURITY
下载PDF
Cinobufagin, a bufadienolide from traditional Chinese medicine Bufo bufo gargarizans CANTOR, inhibits PC3 cell growth in vitro and in vivo 被引量:5
2
作者 Tianli Niu Liye Zhao +7 位作者 Xuyao Lin Yangkai Cai Shuhui Chen Mingkai Wang Li Zhou Hongyang Ding Xiaohan Yu Guozheng Qin 《Journal of Traditional Chinese Medical Sciences》 2019年第2期175-183,共9页
Objective:To explore the effects of cinobufagin (CBF),an active component of toad venom (Bufo bufo gargarizans CANTOR),on the proliferation and apoptosis of PC3 human prostate cancer cells in vitro and preliminarily i... Objective:To explore the effects of cinobufagin (CBF),an active component of toad venom (Bufo bufo gargarizans CANTOR),on the proliferation and apoptosis of PC3 human prostate cancer cells in vitro and preliminarily investigate the mechanism of CBF in suppressing tumor cell growth in vivo.Methods:The effect of CBF on PC3 cells proliferation was detected using MTT assay.The morphological changes of PC3 cells were observed under an optical microscope.Colony formation assays were used to observe the CBF effect on colony formation by PC3 cells.PC3 cell apoptosis after treatment with CBF for 48 hours was monitored using flow cytometry.Furthermore,the effect of CBF on the expression of myeloid cell leukemia-1 (MCL-1) and related apoptotic proteins was examined using western blotting.A xenograft model was established in BALB/c nude mice to evaluate the effect of CBF on prostate cancer in vivo.Results:The MT-T assay results illustrated that PC3 cell proliferation was inhibited in vitro by CBF in a concentration-and time-dependent manner.Compared with the control group findings,CBF significantly inhibited the formation of PC3 cells (P =.005).Flow cytometry revealed that after treatment with 50 nM CBF for 48 hours,the apoptotic rate of PC3 cells was 41.97 (5.16)%,indicating that CBF could significantly induce its apoptosis (P =.003).In addition,optical and fluorescence microscopy uncovered remarkable inhibition of cell proliferation accompanied by morphologic changes.The western blotting result indicated that CBF obviously downregulated the expression of the anti-apoptotic protein MCL-1.Most importantly,ClBF reduced the carcinogenicity of PC3 xenografts in nude mice.Conclusion:CBF can inhibit the growth of PC3 cells both in vitro and in vivo and induce apoptosis of tumor cells.The corresponding mechanism may be correlated with the activation of caspase family proteins via MCL-1. 展开更多
关键词 Prostate cancer cinobufagin CELL proliferation CELL apoptosis MCL-1
下载PDF
Meta-analysis of Cinobufagin Capsules combined with chemotherapy in treating gastric cancer
3
作者 Yan-Ping Ge Yong Xu +2 位作者 Lei Zhu Jing Xing Hong Shen 《Journal of Hainan Medical University》 2021年第12期14-19,共6页
Objective:To evaluate the efficacy and safety of Cinobufagin capsules combined with chemotherapy in the treatment of gastric cancer by Meta-analysis.Methods:Randomized controlled trials(RCTs)of Cinobufagin capsules co... Objective:To evaluate the efficacy and safety of Cinobufagin capsules combined with chemotherapy in the treatment of gastric cancer by Meta-analysis.Methods:Randomized controlled trials(RCTs)of Cinobufagin capsules combined with chemotherapy for gastric cancer included in Chinese database(VIP,CNKI,WanFang,CBM)and English database(PubMed,Cochrane Library,EMBase)were retrieved from the inception to June 2020.Data extraction and methodological quality evaluation were carried out for the included literature.The methodological quality assessment was based on Cochrane bias risk assessment tool.RevMan 5.3 and GRADEpro 3.6 were used for meta-analysis and evidence quality assessment,respectively.Results:12 trials with 830 patients were included in the review.Meta-analysis results showed that:the addition of Cinobufagin capsules for gastric cancer enhanced the objective remission rate(ORR)(RR=1.65,95%CI[1.41,1.93],P<0.00001);improved quality of Life Score(KPS score)(RR=1.77,95%CI[1.43,2.19],P<0.00001);reduced the incidence of nausea and vomiting(RR=0.46,95%CI[0.29,0.74],P=0.001),leukocyte toxicity(RR=0.40,95%CI[0.25,0.64],P<0.0001),and platelet toxicity(RR=0.45,95%CI[0.22,0.93],P=0.03);increased the level of CD4+(MD=6.99,95%CI[4.32,9.66],P<0.00001)was better than chemotherapy alone,with statistically significant differences.The quality of evidence is low by GRADE evaluation.Conclusion:In chemotherapy for gastric cancer,combined with Cinobufagin capsule has better efficacy and safety. 展开更多
关键词 cinobufagin Capsules CHEMOTHERAPY Gastric cancer META-ANALYSIS
下载PDF
Clinical Study on TACE Combined with Elemene Injection and Cinobufagin Injection Respectively for Middle and Advanced Primary Hepatic Carcinoma
4
作者 Xinyue Cui Zhizhong Ma 《Advances in Modern Oncology Research》 2020年第3期1-5,共5页
Objective: To observe and compare the differences in the clinical effect and the incidences of adverse reactions oftranscatheter arterial chemoembolization(TACE) combined with elemene injection and cinobufagin injecti... Objective: To observe and compare the differences in the clinical effect and the incidences of adverse reactions oftranscatheter arterial chemoembolization(TACE) combined with elemene injection and cinobufagin injection respectively for middleand advanced primary hepatic carcinoma. Methods: A total of 104 cases of patients with middle and advanced primary hepaticcarcinoma who were treated in the oncology department from August 2018 to January 2020 were included as the study objects, andwere randomly divided into two groups according to different treatment regimens, 52 cases in each group. Both groups were treatedwith TACE once;the cinobufagin injection group was given intravenous infusion with 500 mL of 5% glucose injection and 10 mLof cinobufagin injection once a day. The elemene injection group was given intravenous infusion with elemene injection of 0.4 geach time and once a day. Both groups were treated for two courses, 15 days of continuous treatment with a rest of 15 days beingone course. The clinical effect, the changes in the indexes of liver function including alanine amino transferase(ALT), aspartatetransaminase(AST) and total bilirubin(TBil), the scores of alpha-fetoprotein(AFP) and Karnofsky (KPS) and tumor volumes aswell as the difference in the incidences of adverse reactions between the two groups were observed and compared. Results: Thetotal clinical effective rate was 88.46% in the elemene injection group and 71.15% in the cinobufagin injection group, and thedifference was significant(P<0.05). After treatment, the levels of ALT, AST and TBil in serum in the two groups were significantlydecreased when compared with those before treatment, differences being significant(P<0.05). There was no significant differencebeing found in the comparison of the levels of ALT, AST and TBil in serum between the two groups (P>0.05). After treatment, thedecrease of AFP, tumor volume and the increase of KPS scores in the elemene injection group were significantly more than thosein the cinobufagin injection group, differences being significant (P<0.01). During treatment, there was no significant differencebeing found in the comparison of the total incidences of adverse reactions between the two groups(P>0.05). The adverse reactionsin the cinobufagin injection group were mainly nausea and vomiting, with higher incidence than that in the elemene injection group,the difference being significant (P<0.05). The adverse reactions in the elemene injection group were mainly pain at the injectionsite, with higher incidence than that in the cinobufagin injection group, the difference being significant (P<0.05). Conclusion: Thetherapy of elemene injection combined with TACE for middle and advanced primary hepatic carcinoma has better clinical effect thanthat of cinobufagin injection, but the occ. 展开更多
关键词 Middle and advanced primary hepatic carcinoma Elemene injection cinobufagin injection Transcatheter arterial chemoembolization Liver function Alpha-fetoprotein Tumor volume Adverse reactions
下载PDF
A clinical study on the prevention of phlebitis caused by Cinobufagin using hand exercise combined with Jinhuang ointment
5
作者 Yan-Li Min Yan-Ping Wang 《TMR Integrative Nursing》 2020年第3期91-96,共6页
Objective:The aim of this study is to observe the clinical effect of hand exercise combined with jinhuang ointment on the prevention of phlebitis due to cinobufagin.Methods:A total of 90 cancer patients who have been ... Objective:The aim of this study is to observe the clinical effect of hand exercise combined with jinhuang ointment on the prevention of phlebitis due to cinobufagin.Methods:A total of 90 cancer patients who have been receiving intravenous(Ⅳ)infusion of cinobufagin from May 2018 to June 2019 in the oncology department of our hospital were selected.They were then divided into three groups in a random manner,which include 30 cases in the control group,30 cases in the jinhuang ointment group,and 30 cases in the group of hand exercise combined with jinhuang ointment.The control group had a routine care before cinobufagin was infused from the first day of hospitalization.During the routine care mentioned previously,the jinhuang ointment group was given locally jinhuang ointment inunction,qd,and kept for 6 hours.Hand exercises were then done on the combined group excluding jinhuang ointment application,qd,at 10min.After treatment for 1 week,the phlebitis and pain incidences on the venipuncture site were then compared between the three groups.Results:After the 1-week treatment,the incidences of grade Ⅰ/Ⅱ phlebitis in the control group,the jinhuang ointment group,and the group of hand exercise combined with jinhuang ointment were 53.5%,23.3%,and 10%,respectively.The results have shown a significant decrease in the jinhuang ointment group and the combined group as in comparison with the control group(P=0.0169,P=0.0003).Even with the incidence of the combined group being lower than that of the jinhuang ointment group,no statistically significant difference(P=0.1659)was found.The incidences of grade Ⅲ/Ⅳ phlebitis in the control group,the jinhuang ointment group,and the group of hand exercise combined with jinhuang ointment were 23.3%,3.3%,and 3.3%,respectively.Both the jinhuang ointment group and the combined group had significantly lower results than that of the control group(P=0.0003,P=0.0227).There was no difference in the results of the combined group and the jinhuang ointment group.The incidences of pain in the control group,the jinhuang ointment group,and the group of hand exercise combined with jinhuang ointment were 56.7%,36.7%,and 20%,respectively.There was no significant difference in the results of the jinhuang ointment group and the control group(P=0.1205);the combined group has shown a significant decrease in the incidence compared with the control group(P=0.0035);the incidence of pain in the combined group was lower than that of the jinhuang ointment group,but without a statistical difference(P=0.1520).Conclusion:Hand exercise together with jinhuang ointment inunction can significantly reduce the incidence of phlebitis produced by cinobufagin. 展开更多
关键词 Hand exercise Jinhuang ointment cinobufagin PHLEBITIS
下载PDF
One new bufadienolide biotransformed from cinobufagin by Cunninghamella elegans 被引量:3
6
作者 Li Qiao Yu Zhi Zhou Huan Chen Jia Qing Cao Yue Hu Pei 《Chinese Chemical Letters》 SCIE CAS CSCD 2008年第3期299-301,共3页
Cunninghamella elegans 被采用了让华蟾蜍精(1 ) 的简历转变负担得起一代谢物。转变产品的结构作为 7 β被描绘了, 12 β - dihydroxylcinobufagin (2 ) 。产品 2 是新混合物。在 vitro,简历转变产品和 substrate-cinobufagin 的细... Cunninghamella elegans 被采用了让华蟾蜍精(1 ) 的简历转变负担得起一代谢物。转变产品的结构作为 7 β被描绘了, 12 β - dihydroxylcinobufagin (2 ) 。产品 2 是新混合物。在 vitro,简历转变产品和 substrate-cinobufagin 的细胞毒素的活动是对 HeLa 的 assayed;他们都显示出细胞毒素的活动。 展开更多
关键词 华蟾蜍精 生物转化 越瓜 药物制造
下载PDF
Intestinal Transport and Biotransformation of Resibufogenin and Cinobufagin in Chan Su via HPLC/APCI-MS^n 被引量:2
7
作者 HAN Tian-jiao WANG Qing +3 位作者 SONG Feng-rui LIU Zhong-ying LIU Zhi-qiang LIU Shu-ying 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2011年第3期380-384,共5页
In vitro models of human colon carcinoma cell line(Caco-2 cell monolayer) and human intestinal bacteria were used to investigate the intestinal transport and biotransformation of resibufogenin and cinobufagin in Chan ... In vitro models of human colon carcinoma cell line(Caco-2 cell monolayer) and human intestinal bacteria were used to investigate the intestinal transport and biotransformation of resibufogenin and cinobufagin in Chan Su by HPLC/APCI-MSn. The experimental results of Caco-2 cell monolayer demonstrate that the apparent permeability coefficients(Papp) of resibufogenin and cinobufagin are higher than 10-6 cm/s, which indicates that both resibufogenin and cinobufagin have a good absorption in the small intestine. And the biotransformation result of human intestinal bacteria shows that resibufogenin has been transformed to 3-epiresibufogenin and cinobufagin has been transformed to 3-epicinobufagin, deacetylcinobufagin and 3-epideacetycinobufagin, respectively. 展开更多
关键词 生物转化 肠道细菌 HPLC APCI MSN 运输 细胞株
下载PDF
Crystal Structure and Anticancer Properties of Cinobufagin 3-Hemisuberate Methyl Ester 被引量:1
8
作者 张冤 冯娟 +2 位作者 叶文才 田海妍 江仁望 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 2014年第5期790-794,共5页
The title compound cinobufagin 3-hemisuberate methyl ester(1) was isolated from the venom of Bufo bufo gargarizans CANTOR. The crystal structure of 1, C35H48O9, was determined by single-crystal X-ray diffraction analy... The title compound cinobufagin 3-hemisuberate methyl ester(1) was isolated from the venom of Bufo bufo gargarizans CANTOR. The crystal structure of 1, C35H48O9, was determined by single-crystal X-ray diffraction analysis. It belongs to orthorhombic, space group P212121 with a = 8.9338(3), b = 16.2970(4), c = 22.4019(6) , V = 3261.59(16) 3, Mr = 612.73, Z = 4, Dc = 1.248 g/cm3, μ = 0.725 mm-1, F(000) = 1320, S = 1.040, the final R = 0.0374 and wR = 0.0412 for 4458 unique reflections, of which 4088 were observed(I > 2σ(I)). In the solid state, short intermolecular C-H...O interactions involving a methine and the ester carbonyl group in cinobufagin moiety and a methyl in the suberate moiety linked adjacent molecules into a three-dimensional network. Detailed analysis of the 1H-NMR data showed that X-ray structure of 1 would be expected to closely resemble the solution conformation in chloroform. Compound 1 was inactive for the inhibition of PC3 and HepG2 cancer cells, but the parent compound cinobufagin showed potent inhibition with IC50 values of 0.145 and 5.48 μM, respectively, indicating that esterification at C(3) decreased the cytotoxic effect of 1. 展开更多
关键词 中华大蟾蜍 晶体结构 甲酯 单晶X射线衍射分析 标题化合物 特性 抗癌 X射线结构
下载PDF
华蟾素对肝癌患者介入术后外周血Bcl-2和cyclinD1蛋白表达水平的影响
9
作者 杨海 程维刚 +1 位作者 杨佳宝 岳彩娟 《辽宁中医杂志》 CAS 北大核心 2024年第1期101-105,共5页
目的观察华蟾素对肝癌患者介入术后外周血Bcl-2和细胞周期蛋白(cyclinD1)表达水平的影响。方法本次研究对象在2020年5月—2021年5月于医院进行介入术治疗的肝癌患者中选择100例,随机分为两组,50例患者给予患者常规介入治疗(常规介入组)... 目的观察华蟾素对肝癌患者介入术后外周血Bcl-2和细胞周期蛋白(cyclinD1)表达水平的影响。方法本次研究对象在2020年5月—2021年5月于医院进行介入术治疗的肝癌患者中选择100例,随机分为两组,50例患者给予患者常规介入治疗(常规介入组),50例患者在常规化疗的基础上加用华蟾素治疗(华蟾素组)。检测患者的Bax、Bcl-2、cyclinD1水平及肝功能指标[甲胎蛋白(AFP)、谷丙转氨酶(ALT)、总胆红素(TBIL)、谷草转氨酶(AST)]、免疫功能指标[免疫球蛋白G(IgG)、自然杀伤(NK)细胞、T淋巴细胞亚群(CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+))],比较两组卡氏(KPS)评分、肝功能分级标准(Child-Pugh)评分,评价疗效,观察两组不良反应发生情况。结果华蟾素组患者治疗后的Bax水平高于常规介入组(P<0.05),Bcl-2、cyclinD1水平低于常规介入组(P<0.05);华蟾素组患者治疗后的AFP、TBIL、AST水平低于常规介入组(P<0.05),ALT水平高于常规介入组(P<0.05);华蟾素组患者治疗后的IgG、NK细胞、CD_(4)^(+)水平高于常规介入组(P<0.05),CD_(4)^(+)/CD_(8)^(+)水平低于常规介入组(P<0.05);华蟾素组患者治疗后的KPS评分高于常规介入组(P<0.05),Child-Pugh评分低于常规介入组(P<0.05);华蟾素组患者治疗有效率为92.00%,高于常规介入组的74.00%(P<0.05);华蟾素组患者的不良反应发生率为20.00%,低于常规介入组的44.00%(P<0.05)。结论华蟾素可以下调肝癌患者介入术后外周血Bcl-2和cyclinD1蛋白表达水平,上调Bax水平,促进肿瘤细胞凋亡;同时可以增强患者的肝功能和免疫功能,提高生活质量,改善预后;还能提高肝癌介入治疗疗效,降低发生不良反应的风险。 展开更多
关键词 肝癌 华蟾素 BCL-2 CYCLIND1 肝功能
原文传递
华蟾素胶囊联合新辅助化疗方案治疗HER2阳性乳腺癌临床研究
10
作者 叶露 陈鸿 陆巧妮 《中国医学创新》 CAS 2024年第11期134-139,共6页
目的:探讨华蟾素胶囊联合新辅助化疗方案治疗HER2阳性乳腺癌的临床效果。方法:纳入2022年2月—2023年2月于南昌市人民医院就诊的86例HER2阳性乳腺癌患者,使用随机数字表法将患者分为观察组和对照组,各43例,对照组予以曲妥珠单抗+帕妥珠... 目的:探讨华蟾素胶囊联合新辅助化疗方案治疗HER2阳性乳腺癌的临床效果。方法:纳入2022年2月—2023年2月于南昌市人民医院就诊的86例HER2阳性乳腺癌患者,使用随机数字表法将患者分为观察组和对照组,各43例,对照组予以曲妥珠单抗+帕妥珠单抗+紫杉类联合铂类新辅助化疗方案,观察组在对照组新辅助化疗方案基础上加用华蟾素胶囊治疗。比较两组临床疗效、肿瘤退缩分级、血清相关指标[血清癌胚抗原(CEA)、糖类抗原153(CA153)、组织多肽特异抗原(TPS)、免疫球蛋白(Ig)A、Ig M和T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))]、生活质量[乳腺癌患者生活质量测定量表中文版(FACT-B)]及不良反应。结果:两组客观缓解率(51.16%vs 41.86%)、疾病控制率(81.40%vs74.42%)比较,差异均无统计学意义(P>0.05);两组肿瘤退缩分级比较,差异无统计学意义(P>0.05);治疗后,两组CEA、CA153、TPS水平均较治疗前降低,观察组均低于对照组(P<0.05);治疗后,观察组Ig A、Ig M、CD3^(+)、CD4^(+)水平均高于对照组(P<0.05);两组治疗前后CD8^(+)水平比较,差异无统计学意义(P>0.05);治疗后,观察组生理状况、情感状况、社会/家庭状况、附加关注评分均高于对照组,差异均有统计学意义(P<0.05);观察组头痛头晕、消化道不适、心脏毒性反应、肝肾损伤及骨髓抑制发生率均低于对照组(P<0.05)。结论:华蟾素胶囊联合新辅助化疗方案治疗HER2阳性乳腺癌,可在一定程度上抑制肿瘤进展,改善患者免疫失衡及生活质量水平,降低化疗毒副反应。 展开更多
关键词 华蟾素胶囊 新辅助化疗 HER2阳性乳腺癌 生活质量 肿瘤退缩
下载PDF
Novel Cinobufagin Oxime Ether Derivatives as Potential Na+/K+-ATPase Inhibitors: Synthesis, Biological Screening and Molecular Docking 被引量:1
11
作者 LIANG Guangping CHUNG Tseyu +4 位作者 GUO Jinhua ZHANG Rongrong XU Wei TZEN Jason T.C JIANG Renwang 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2017年第3期378-383,共6页
关键词 ATPASE 分子对接 衍生物 肟醚 活性筛选 Na 蟾酥 合成
原文传递
Identification of Cinobufagin and Resibufogenin as Inhibitors of Enterovirus 71 Infection 被引量:1
12
作者 CHEN Jiawen XU Lin +4 位作者 SUN Shiyang ZHANG Huafei MA Tonghui SU Weiheng JIANG Chunlai 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2014年第6期953-958,共6页
关键词 肠道病毒 感染 抑制剂 鉴定 抑制浓度 细胞毒性 萤光素酶
原文传递
华蟾素通过铁死亡途径抑制上皮性卵巢癌细胞增殖、迁移与侵袭
13
作者 孙慧霞 郭哲 +4 位作者 许静 王青 段运峥 朱玲新 王启船 《临床与病理杂志》 CAS 2023年第12期2090-2098,共9页
目的:铁死亡在包含卵巢癌在内的多种癌症进展中发挥重要作用,是癌症干预的潜在策略。华蟾素(cinobufagin,CINO)已在多种癌症中发挥抗肿瘤作用,而其对上皮性卵巢癌中的作用及其对铁死亡的影响并不清楚。本研究旨在探究CINO对上皮性卵巢... 目的:铁死亡在包含卵巢癌在内的多种癌症进展中发挥重要作用,是癌症干预的潜在策略。华蟾素(cinobufagin,CINO)已在多种癌症中发挥抗肿瘤作用,而其对上皮性卵巢癌中的作用及其对铁死亡的影响并不清楚。本研究旨在探究CINO对上皮性卵巢癌恶性生物学行为的影响,并初步探索其铁死亡的相关机制。方法:梯度浓度(0、0.1、1.0、10.0 mg/mL)CINO处理卵巢癌细胞株A2780和SKOV3,采用5-乙炔基-2’-脱氧尿苷(5-ethynyl-2’-deoxyuridine,EDU)染色法检测增殖;Transwell法检测细胞迁移与侵袭;FerroOrange染色评估细胞内Fe2+含量;酶联免疫吸附测定(enzyme-linked immunosorbent assay,ELISA)法检测细胞内4-羟基壬烯醛(4-hydroxynonenal,4-HNE)水平;二氢乙锭(dihydroethidium,DHE)探针试剂盒法检测细胞内活性氧(reactive oxygen species,ROS)水平;蛋白质印迹法检测溶质载体家族7成员11(solute carrier family 7 member 11,SLC7A11)和转铁蛋白受体1(transferrin receptor 1,TFR1)表达。采用铁死亡抑制剂Ferrostatin-1(Fer-1)和铁离子螯合剂甲磺酸去铁胺(deferoxamine mesylate,DFO)预处理A2780和SKOV3细胞,再给予10.0 mg/mL CINO处理,分别检测细胞增殖、迁移与侵袭情况。结果:CINO能剂量依赖性抑制A2780细胞增殖、侵袭及迁移,增加细胞内Fe2+及4-HNE水平,降低SLC7A11表达,并增加TFR1表达(均P<0.05)。Fer-1和DFO可部分逆转CINO对卵巢癌细胞增殖、迁移与侵袭的抑制作用(均P<0.05)。结论:CINO抑制卵巢癌细胞的增殖、迁移与侵袭,其作用可能与其通过调节SLC7A11/TFR1信号通路增加卵巢癌细胞铁死亡有关。 展开更多
关键词 华蟾素 上皮性卵巢癌 增殖 迁移 侵袭 铁死亡
下载PDF
华蟾酥毒基通过调控circNFIX/miR-577通路抑制乳腺癌MDA-MB-231细胞的增殖、迁移和侵袭 被引量:2
14
作者 何孙香 吴中伟 刘梅芬 《中国免疫学杂志》 CAS CSCD 北大核心 2023年第4期770-776,共7页
目的:研究华蟾酥毒基(CnBu)对乳腺癌细胞MDA-MB-231恶性生物学行为的影响,并探讨其机制是否与调控环状RNA核因子IX(circNFIX)和miR-577表达相关。方法:将MDA-MB-231细胞分为对照(Con)组、CnBu-低剂量(L)组、CnBu-中剂量(M)组、CnBu-高剂... 目的:研究华蟾酥毒基(CnBu)对乳腺癌细胞MDA-MB-231恶性生物学行为的影响,并探讨其机制是否与调控环状RNA核因子IX(circNFIX)和miR-577表达相关。方法:将MDA-MB-231细胞分为对照(Con)组、CnBu-低剂量(L)组、CnBu-中剂量(M)组、CnBu-高剂量(H)组、si-NC组、si-circNFIX组、pcDNA组、pcDNA-circNFIX组、CnBu+pcDNA组、CnBu+pcDNAcircNFIX组。MTT、Transwell实验分析细胞增殖、迁移和侵袭能力,Westernblot分析Ki-67、基质金属蛋白酶2(MMP-2)和MMP-9蛋白表达。RT-qPCR分析circNFIX、miR-577表达量。双荧光素酶报告实验和RT-qPCR验证circNFIX和miR-577的靶向调控关系。结果:CnBu以剂量依赖方式下调Ki-67、MMP-2、MMP-9蛋白和circNFIX表达(P<0.05),上调miR-577表达(P<0.05),减弱MDA-MB-231细胞的增殖、迁移和侵袭能力(P<0.05)。miR-577与circNFIX序列直接结合,干扰或过表达circNFIX可显著提高或降低miR-577表达水平(P<0.05)。干扰circNFIX表达显著下调Ki-67、MMP-2、MMP-9蛋白表达(P<0.05),减弱MDA-MB-231细胞的增殖、迁移和侵袭能力(P<0.05)。过表达circNFIX显著减弱CnBu对MDA-MB-231细胞增殖、迁移、侵袭及相关蛋白表达的影响(P<0.05)。结论:CnBu可抑制乳腺癌MDA-MB-231细胞的增殖、迁移和侵袭,可能通过下调circNFIX/miR-577通路实现。 展开更多
关键词 华蟾酥毒基 乳腺癌 细胞增殖 迁移 侵袭 circNFIX miR-577
下载PDF
基于转录组学探讨华蟾酥毒基抑制肝癌细胞增殖的作用机制 被引量:1
15
作者 孔晨玥 杨文娜 +1 位作者 闫秀丽 张辉 《上海中医药杂志》 CSCD 2023年第8期49-56,共8页
目的观察华蟾酥毒基(CBF)对肝癌细胞增殖的抑制作用,采用转录组学测序技术揭示相关基因及信号通路,探讨CBF抗肝细胞癌(HCC)的可能作用机制。方法用不同浓度的CBF(0、2、4、8、16和32μmol·L^(-1))处理人HCC细胞SMMC-7721和JHH7,时... 目的观察华蟾酥毒基(CBF)对肝癌细胞增殖的抑制作用,采用转录组学测序技术揭示相关基因及信号通路,探讨CBF抗肝细胞癌(HCC)的可能作用机制。方法用不同浓度的CBF(0、2、4、8、16和32μmol·L^(-1))处理人HCC细胞SMMC-7721和JHH7,时间梯度为24、48和72 h,WST-1试剂盒检测细胞增殖情况。根据WST-1试剂盒检测结果,用CBF 2μmol·L^(-1)干预SMMC-7721和JHH7细胞24 h,然后进行转录组学基因表达测序分析差异表达基因,并行生物信息学分析。基于文献报道及TCGA数据库观察部分差异表达基因在HCC组织中的表达情况,采用实时荧光定量逆转录聚合酶链式反应(RT-qPCR)技术检测并验证CBF靶基因的表达情况。结果①CBF对SMMC-7721和JHH7细胞具有抑制增殖作用,且呈浓度-时间依赖性。②转录组学测序结果显示,经CBF干预后,SMMC-7721细胞获得差异表达基因共计578个(其中上调基因309个、下调基因269个),JHH7细胞获得差异表达基因共计611个(其中上调基因349个、下调基因262个),两组细胞获得的交集基因共有106个(差异倍数>2,P<0.05)。③生物信息学分析显示,激活转录因子3(ATF3)、羰基还原酶1(CBR1)、细胞骨架相关蛋白4(CKAP4)、生长停滞和DNA损伤可诱导蛋白β(GADD45B)、钾二孔域通道亚科K成员5(KCNK5)、起源识别复合亚基5(ORC5)基因的转录水平在HCC组织中呈异常表达并与患者预后相关。④RT-qPCR结果显示,CBF能促进ATF3、KCNK5和GADD45B基因的表达,抑制CBR1、CKAP4和ORC5基因的表达,与测序结果一致。结论CBF具有抑制HCC细胞增殖的作用,其机制可能与调控ATF3、KCNK5、GADD45B、CBR1、CKAP4和ORC5基因表达有关。 展开更多
关键词 华蟾酥毒基 肝癌细胞 转录组学 作用机制 中药研究
原文传递
华蟾素调控HIF-1α/VEGF通路逆转结肠癌HCT15/5-FU细胞耐药的体外研究
16
作者 赵秦英 吴悦 +4 位作者 桂仲璇 张泉 叶映泉 王高翔 张梅 《安徽医科大学学报》 CAS 北大核心 2023年第6期902-907,共6页
目的探讨华蟾素(CINO)联合5-氟尿嘧啶(5-FU)对人源结肠癌(CRC)耐药细胞株HCT15/5-FU的逆转作用,明确缺氧诱导因子(HIF-1α)/血管内皮生长因子(VEGF)通路在逆转结肠癌化疗耐药中的调控作用。方法MTT法检测细胞耐药性及耐药指数的变化,流... 目的探讨华蟾素(CINO)联合5-氟尿嘧啶(5-FU)对人源结肠癌(CRC)耐药细胞株HCT15/5-FU的逆转作用,明确缺氧诱导因子(HIF-1α)/血管内皮生长因子(VEGF)通路在逆转结肠癌化疗耐药中的调控作用。方法MTT法检测细胞耐药性及耐药指数的变化,流式细胞术评价细胞凋亡的情况,划痕实验和Transwell法检测细胞迁移和侵袭能力的变化。Western blot检测上皮间充质转化(EMT)相关蛋白及HIF-1α/VEGF通路相关蛋白的表达。结果与HCT15细胞相比,HCT15/5-FU的耐药指数约为8.720。CINO联合5-FU作用后,能够明显提升HCT15/5-FU细胞的药物敏感性,降低耐药指数,剂量依赖性地上调细胞凋亡水平、抑制细胞迁移和侵袭能力;Western blot结果显示CINO联合5-FU作用后能够抑制EMT及HIF-1α/VEGF通路的活性。结论体外研究显示,华蟾素具有逆转结肠癌5-FU耐药的作用,其机制可能与调节HIF-1α/VEGF通路抑制EMT、血管生成有关。 展开更多
关键词 华蟾素 HIF-1α/VEGF 结肠癌 5-FU耐药
下载PDF
华蟾素注射液对胃癌细胞MGC-803增殖、迁移和侵袭能力及上皮-间质转化的影响
17
作者 涂雅婷 王萌 +1 位作者 程卉 李庆林 《安徽中医药大学学报》 CAS 2023年第3期67-71,共5页
目的 探究华蟾素(cinobufagin,CBG)注射液对人胃癌细胞MGC803增殖、迁移和侵袭能力以及上皮-间质转化(epithelial-mesenchymal transition,EMT)的影响。方法 CCK-8检测CBG注射液对MGC-803存活率的影响;倒置显微镜下观察CBG注射液对MGC-... 目的 探究华蟾素(cinobufagin,CBG)注射液对人胃癌细胞MGC803增殖、迁移和侵袭能力以及上皮-间质转化(epithelial-mesenchymal transition,EMT)的影响。方法 CCK-8检测CBG注射液对MGC-803存活率的影响;倒置显微镜下观察CBG注射液对MGC-803形态的影响;采用细胞划痕实验和Transwell小室检测CBG注射液对胃癌细胞迁移和侵袭能力的影响;Western blot检测人胃癌细胞MGC-803中E-cadherin、N-cadherin、Vimentin和Snail蛋白表达水平。结果 华蟾素注射液能显著抑制MGC-803细胞的增殖、迁移与侵袭(P<0.05),且呈剂量依赖性。Western blot检测结果显示,CBG注射液能显著上调E-cadherin蛋白表达水平(P<0.05),显著下调N-cadherin、Vimentin、Snail蛋白表达水平(P<0.05)。结论 华蟾素注射液可以抑制胃癌细胞MGC-803的增殖、迁移侵袭及EMT。 展开更多
关键词 华蟾素注射液 胃癌细胞 侵袭 转移 上皮-间质转化
下载PDF
华蟾素注射液联合西医疗法治疗肝癌有效性与安全性的系统评价Meta分析
18
作者 任思思 范妤 +4 位作者 郭东艳 翟秉涛 李京涛 史晓燕 段丽芳 《海南医学院学报》 CAS 2023年第6期452-462,共11页
目的:评价华蟾素注射液治疗肝癌的临床有效性及安全性。方法:计算机检索Pubmed数据库、Embase数据库、Cochrane Library数据库、中国知网(CNKI)、万方数据库(WanFang)、维普数据库(VIP)、中国生物医学文献服务系统(SinoMed)检索有关华... 目的:评价华蟾素注射液治疗肝癌的临床有效性及安全性。方法:计算机检索Pubmed数据库、Embase数据库、Cochrane Library数据库、中国知网(CNKI)、万方数据库(WanFang)、维普数据库(VIP)、中国生物医学文献服务系统(SinoMed)检索有关华蟾素注射液联合西医治疗原发性肝癌的随机对照实验,检索时间均为建库至2021年6月4日。由2位独立的研究员分别按照纳入标准对文章进行系统筛选、文献纳入、质量评估,采用RevMan 5.4软件对数据进行Meta分析。结果:共纳入30项研究,总计2355例患者。华蟾素注射液联合西医治疗相比于常规西医治疗临床有效率更高[RR=1.16,95%CI=(1.11,1.22),P<0.00001],能够有效减小瘤体大小[RR=1.33,95%CI=(1.17,1.51),P<0.00001]、延长患者生存时间[RR=1.41,95%CI=(1.31,1.52),P<0.00001]、提高生活质量[RR=1.37,95%CI=(1.19,1.57),P<0.00001]、改善患者肝功能[RR=−14.52,95%CI=(−16.15,−12.88),P<0.00001],减轻骨髓抑制[RR=0.44,95%CI=(0.31,0.62),P<0.00001]等不良反应[RR=0.94,95%CI=(0.85,1.42),P=0.25]的发生。结论:华蟾素注射液联合西医疗法可有效改善原发性肝癌的临床症状,且安全性好。但纳入文献的方法学质量较低,影响结局的客观性,尚需要更加全面的多样本、多中心、随机双盲对照实验进行验证。 展开更多
关键词 华蟾素注射液 原发性肝癌 Meta分析 有效性 安全性
下载PDF
高效液相色谱-质谱联用法测定喉症丸中华蟾酥毒基和脂蟾毒配基
19
作者 李志东 葛朝晖 张海娟 《中兽医医药杂志》 CAS 2023年第5期57-59,共3页
建立高效液相色谱-质谱联用法(HPLC-MS)测定喉症丸中华蟾酥毒基和脂蟾毒配基含量的方法。采用HPLC-MS正离子多反应监测模式进行测定,色谱柱为Thermo Hypersil BDS C18(250.0 mm×4.6 mm,5μm),流动相为乙腈-1%乙酸溶液(38∶62),流速... 建立高效液相色谱-质谱联用法(HPLC-MS)测定喉症丸中华蟾酥毒基和脂蟾毒配基含量的方法。采用HPLC-MS正离子多反应监测模式进行测定,色谱柱为Thermo Hypersil BDS C18(250.0 mm×4.6 mm,5μm),流动相为乙腈-1%乙酸溶液(38∶62),流速为0.5 mL/min,检测波长为296 nm,柱温为20℃。质谱条件:鞘气流速40 arb,辅气流速5 arb,喷雾电压4.5 kV,毛细管温度300℃。结果显示,华蟾酥毒基和脂蟾毒配基的检测质量浓度线性范围均为50~300μg/mL(r=0.9992),重复性试验、精密度试验、稳定性(12 h)试验的RSD均小于1.00%(n=5或n=6),加样回收率分别为101.8%(RSD为2.61%,n=6)和100.9%(RSD为3.20%,n=6)。该方法灵敏度高、重复性好,能准确测定喉症丸中华蟾酥毒基和脂蟾毒配基的含量,可用于喉症丸的质量控制。 展开更多
关键词 喉症丸 高效液相色谱-质谱联用法 华蟾酥毒基 脂蟾毒配基 含量测定
原文传递
上一页 1 2 14 下一页 到第
使用帮助 返回顶部